静脉MR淋巴造影:猪模型可行性及患者概念验证
本研究先在猪模型中评估静脉注射钆对比剂后MR淋巴造影的可行性,发现注射后20–30分钟淋巴液钆浓度超过门静脉和体静脉,存在「淋巴期」。随后在16例患者中验证,胸导管/下腔静脉信号强度比从1分钟的0.49±0.21升至20分钟的1.47±0.32(P<.001),提示该技术可无创显示肝及肠系膜淋巴管。
要点
- 静脉注射钆对比剂后20分钟左右为「淋巴期」,此时胸导管及肝、肠系膜淋巴管可被显示
- 胸导管/下腔静脉信号比从1分钟到20分钟显著升高,可用于判断淋巴增强是否充分
- 该技术有望弥补传统DCMRL对肝和肠系膜淋巴管显示不全的不足
核心结论
- 静脉MR淋巴造影有潜力成为无创全面显示淋巴系统的技术,包括常规淋巴研究如DCMRL常难以完整评估的肝和肠系膜淋巴管
研究设计与样本
- 动物实验部分:2只猪分别静脉注射钆特酸葡胺和钆塞酸二钠后采集体静脉、门静脉及淋巴液样本进行钆浓度定量
- 动物实验部分:另1只动物分别行静脉MR淋巴造影和动态对比增强MR淋巴造影,并测量淋巴及血管结构的信号强度
- 人体试点研究时间为2024年9月至2025年8月,共16例,平均年龄56.6岁±24.7,其中11例男性
- 人体研究通过比较对比剂注射后1分钟和20分钟胸导管/下腔静脉信号强度比评估淋巴增强情况
- 人体研究采用配对t检验分析同一受试者两个时间点之间的差异
关键影像表现/征象
- 静脉MR淋巴造影在「淋巴期」不仅显示胸导管和乳糜池,还显示肝和肠系膜淋巴管
诊断标准与关键数值
- 猪体液采样显示淋巴液钆浓度在20–30分钟达峰,并超过门静脉和体静脉浓度,提示存在「淋巴期」
- 人体研究中胸导管/下腔静脉信号强度比从1分钟的0.49±0.21上升到20分钟的1.47±0.32(均为均数±标准差,P<.001)
临床应用与阅片要点
- 阅片时可将对比剂注射后20分钟作为观察肝及肠系膜淋巴管的关键时间窗口
- 胸导管/下腔静脉信号强度比可作为判断淋巴期增强是否满意的辅助指标
局限性
- 人体研究样本量仅为16例,且为试点性质的概念验证研究
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Visualization of the hepatic and mesenteric lymphatics remains challenging despite recent advances in lymphatic imaging, including dynamic contrast-enhanced MR lymphangiography (DCMRL). Purpose To assess the feasibility of intravenous contrast-enhanced MR lymphangiography (IV-MRL) in a swine model and a pilot patient group. Materials and Methods Systemic and portal venous and lymph samples were collected from two swine after intravenous administration of gadolinium (Gd)-based contrast agents (Gd tetraazacyclododecane tetraacetic acid and Gd ethoxybenzyl diethylenetriamine pentaacetic acid; n = 1 each), and Gd quantification was performed. IV-MRL and DCMRL were performed in a separate animal, and the signal intensity (SI) of the lymphatic and vascular structures was measured. In a pilot human study, conducted between September 2024 and August 2025, lymphatic enhancement was assessed by comparing the SI ratios of the thoracic duct (TD) to the inferior vena cava at 1 and 20 minutes after the contrast agent administration. Within-subject differences between time points were analyzed using paired t tests. Results The body fluid sampling study showed that the Gd concentration in the lymph peaked at 20-30 minutes and exceeded those of the portal and systemic veins, indicating the presence of the "lymphatic phase." IV-MRL revealed enhancement of not only the TD and cisterna chyli but also the hepatic and mesenteric lymphatics during the phase. The human pilot study (n = 16; mean age of 56.6 years ± 24.7 [SD]; 11 men) showed a substantial increase in TD/inferior vena cava SI ratio from 0.49 ± 0.21 at 1 minute to 1.47 ± 0.32 at 20 minutes (all values are means ± SDs; P < .001). Conclusion IV-MRL had potential as a noninvasive technique for comprehensive visualization of the lymphatics, including hepatic and mesenteric ones, which are often incompletely assessed by conventional lymphatic studies such as DCMRL. © RSNA, 2026 Supplemental material is available for this article.
引用
- Kwon, Yoon, Hur, et al. Intravenous MR Lymphangiography: Feasibility in a Swine Model and Proof-of-Concept in Patients. Radiology. 2026. PMID: 42411963. doi:10.1148/radiol.252027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。